BEDFORD, Mass.--(BUSINESS WIRE)--Jan.
31, 2005--Spire Corporation (Nasdaq: SPIR):
-- Nano-engineered biological coatings designed to
prevent blood clotting.
-- Biological coatings aimed
at enhancing Spire's hemodialysis product line.
Spire Corporation (Nasdaq:
SPIR) today announced the receipt of a two-year SBIR
Phase II grant of $498,764 from the National Science
Foundation ("NSF") to continue the development
of blood-compatible dialysis catheters, used for the
treatment of end-stage renal disease ("ESRD")
Under Phase I of the program,
Spire demonstrated through in-vitro studies that its
proprietary surface treatment reduces the potential
for catheter related thrombosis. This treatment results
in a nano-engineered biological coating that combines
protein passivation, anticoagulation, and fibriolytic
chemistry that is integrated onto an atomically nano-textured
Mark Little, CEO of Spire Biomedical,
stated, "Vascular access complications cost our
healthcare system more than $2 billion annually. Clotting
of catheters reduces vascular access potency, requiring
intervention and disrupting treatment. Domestically,
industry experts estimate that nearly 600,000 hemodialysis
catheters alone are sold each year with a market value
of more than $100 million. Applying this new technology
to dialysis catheters will provide major benefits
for physicians, hospital staff, and most importantly,
Spire Biomedical offers a full
line of chronic hemodialysis catheters. The Company
is also a leading provider of surface engineering
technology for biomedical devices.
Spire Corporation is a diversified
technology company serving the biomedical, solar energy,
telecommunications and defense industries worldwide
with innovative products and services based upon a
common technology platform.
Roger G. Little